Abstract Background: Tuberculous meningitis is often lethal, and many survivors have disabilities despite antimicrobial treatment and adjunctive glucocorticoid therapy. Standard-dose rifampin has limited central nervous system penetration. Whether high-dose rifampin could improve survival outcomes is unknown. Methods: We performed a double-blind, randomized, placebo-controlled clinical trial involving adults with tuberculous meningitis in Indonesia, South Africa, and Uganda. We...Read More

PROTOCOL Type of study: Observative cohort study Study design: A 2-year follow up cohort study involving adult with probable and definite TB meningitis enrolled in Jakarta and Bandung to assess systemic and local inflammatory responses, pharmacokinetic profile of first line anti-tuberculosis therapy and steroid, outcomes, and paradoxical reaction by conducting cerebrospinal fluid, whole blood, and skin...Read More

PROTOCOL Type of study: Phase III interventional clinical trial Study design: This was a multicenter, double-blind, randomized, placebo-controlled Phase III clinical trial conducted across Indonesia, South Africa, and Uganda between June 2019 and May 2023. Adults with tuberculous meningitis, with or without HIV coinfection, were randomly assigned to receive either high-dose rifampin (35 mg/kg/day) or standard-dose...Read More